Edition:
United Kingdom

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

38.41USD
9:00pm BST
Change (% chg)

$0.26 (+0.68%)
Prev Close
$38.15
Open
$38.16
Day's High
$38.80
Day's Low
$38.16
Volume
958,545
Avg. Vol
1,443,398
52-wk High
$47.81
52-wk Low
$29.53

Latest Key Developments (Source: Significant Developments)

Mylan NV - On May 10, Co's Unit Received Civil Investigative Demand From Civil Division Of DOJ Seeking Information Relating To Pricing, Sale Of Generic Drug Products
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Mylan NV ::MYLAN NV - ON MAY 10, CO'S UNIT RECEIVED CIVIL INVESTIGATIVE DEMAND FROM CIVIL DIVISION OF DOJ SEEKING INFORMATION RELATING TO PRICING,SALE OF GENERIC DRUG PRODUCTS.  Full Article

Mylan Says Continues To Develop Details Of Cost Reduction Initiatives, Including Workforce Actions, Other Restructuring Beyond Programs Already Announced
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Mylan NV ::MYLAN- CONTINUES TO DEVELOP DETAILS OF COST REDUCTION INITIATIVES, INCLUDING WORKFORCE ACTIONS ,OTHER RESTRUCTURING BEYOND PROGRAMS ALREADY ANNOUNCED.MYLAN NV - CONTINUED RESTRUCTURING ACTIONS ARE EXPECTED TO BE IMPLEMENTED THROUGH FISCAL YEAR 2018 -SEC FILING.MYLAN NV - COMPANY NOW ANTICIPATES TOTAL AGGREGATE PRE-TAX CHARGES FOR COMMITTED RESTRUCTURING ACTIVITIES RANGING BETWEEN $500.0 MILLION AND $600.0 MILLION.MYLAN - BELIEVES POTENTIAL ANNUAL SAVINGS FROM COMMITTED RESTRUCTURING ACTIVITIES WILL BE BETWEEN ABOUT $400.0 MILLION AND $475.0 MILLION ONCE FULLY IMPLEMENTED.MYLAN NV - AS ADDITIONAL RESTRUCTURING ACTIVITIES ARE UNDERTAKEN, COMPANY EXPECTS TO INCUR ADDITIONAL COSTS INCLUDING EMPLOYEE RELATED COSTS.  Full Article

Mylan NV: Statement From Mylan's Board Of Directors
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Mylan NV ::STATEMENT FROM MYLAN'S BOARD OF DIRECTORS.MYLAN NV - OUR INTERNATIONAL BUSINESS, NOW REPRESENTS MORE THAN 60% OF COMPANY'S GLOBAL SALES.MYLAN NV - BOARD FORMED STRATEGIC REVIEW COMMITTEE, ACTIVELY EVALUATING WIDE RANGE OF ALTERNATIVES TO UNLOCK TRUE VALUE OF OUR ONE-OF-A-KIND PLATFORM.MYLAN NV - BOARD HAS NOT SET A TIMETABLE FOR ITS EVALUATION OF ALTERNATIVES.MYLAN NV - EXPECT CONTINUED GROWTH IN CO'S INTERNATIONAL BUSINESS.MYLAN - BELIEVE U.S. PUBLIC MARKETS CONTINUE TO "UNDERAPPRECIATE AND UNDERVALUE" CO'S GLOBAL DIVERSIFIED BUSINESS.MYLAN - BELIEVE "NEGATIVE TRENDS & DYNAMICS" PLAYING OUT IN U.S. MARKET PLACE ARE "UNSUSTAINABLE" FOR HEALTHCARE SYSTEM OVER LONG-TERM.MYLAN - BELIEVE CO IS WELL POSITIONED TO "SUCCESSFULLY WEATHER AND NAVIGATE" NEGATIVE TRENDS AND DYNAMICS PLAYING OUT IN U.S. MARKET PLACE.  Full Article

Mylan Reports Q2 earnings per share of $0.07
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Mylan NV ::MYLAN REPORTS SECOND QUARTER 2018 RESULTS AND UPDATES 2018 GUIDANCE.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $4.55 TO $4.90.QTRLY TOTAL REVENUES OF $2.81 BILLION, DOWN 5% COMPARED TO PRIOR YEAR PERIOD..QTRLY U.S. GAAP DILUTED EARNINGS PER ORDINARY SHARE ("U.S. GAAP EPS") OF $0.07.QTRLY ADJUSTED DILUTED EARNINGS PER ORDINARY SHARE ("ADJUSTED EPS") OF $1.07.Q2 EARNINGS PER SHARE VIEW $1.22, REVENUE VIEW $2.96 BILLION -- THOMSON REUTERS I/B/E/S.SEES 2018 ADJUSTED EPS $4.55 - $4.90.SEES 2018 TOTAL REVENUES $11,250 MILLION - $12,250 MILLION.SEES 2018 ADJUSTED FREE CASH FLOW $2,100 MILLION - $2,500 MILLION.FY2018 EARNINGS PER SHARE VIEW $5.25, REVENUE VIEW $12.17 BILLION -- THOMSON REUTERS I/B/E/S.COMPANY COMMENCED A RESTRUCTURING AND REMEDIATION PROGRAM AT MORGANTOWN MANUFACTURING FACILITY.PROGRAM INCLUDES REDUCTION OF WORKFORCE, DISCONTINUATION OF A NUMBER OF PRODUCTS, IS AIMED AT REDUCING COMPLEXITY AT MORGANTOWN FACILITY.MYLAN - EXPECTS REMEDIATION ACTIVITIES, LOWER PRODUCTION LEVELS, NEGATIVE IMPACT ON OPERATIONS AND RELATED EXPENSES TO CONTINUE THROUGH END OF 2018..RESTRUCTURING ACTIONS HAVE HAD A "SIGNIFICANTLY NEGATIVE IMPACT ON PRODUCTION LEVELS, PRODUCT SUPPLY AND OPERATIONS".U.S. FDA RECENTLY COMPLETED AN INSPECTION AT MYLAN'S PLANT IN MORGANTOWN, WEST VIRGINIA AND MADE OBSERVATIONS THROUGH A FORM 483.  Full Article

Mylan NV Says Mylan Inc Entered Into A Revolving Credit Agreement
Monday, 30 Jul 2018 

July 30 (Reuters) - Mylan NV ::MYLAN NV SAYS MYLAN INC ON JULY 27, ENTERED INTO A REVOLVING CREDIT AGREEMENT - SEC FILING.MYLAN - NEW SENIOR REVOLVING CREDIT AGREEMENT CONTAINS REVOLVING CREDIT FACILITY UNDER WHICH CO MAY OBTAIN EXTENSIONS OF CREDIT NOT TO EXCEED $2 BILLION.MYLAN NV - NEW SENIOR REVOLVING FACILITY INCLUDES $200 MILLION SUBFACILITY FOR ISSUANCE OF LETTERS OF CREDIT, $175 MILLION SUBLIMIT FOR SWINGLINE BORROWINGS.  Full Article

Mylan And Fujifilm Kyowa Kirin Biologics Announce Positive CHMP Opinion For Hulio™, Biosimilar Adalimumab
Friday, 27 Jul 2018 

July 27 (Reuters) - Mylan NV ::MYLAN AND FUJIFILM KYOWA KIRIN BIOLOGICS ANNOUNCE POSITIVE CHMP OPINION FOR HULIO™, BIOSIMILAR ADALIMUMAB.MYLAN NV - DECISION OF EUROPEAN COMMISSION ON APPROVAL FOR HULIO IS EXPECTED IN OCT 2018.  Full Article

Mylan Adds To Central Nervous System Portfolio With Launch Of Generic Exelon® Patch
Monday, 9 Jul 2018 

July 9 (Reuters) - Mylan NV ::MYLAN ADDS TO CENTRAL NERVOUS SYSTEM PORTFOLIO WITH LAUNCH OF GENERIC EXELON® PATCH.MYLAN- U.S. LAUNCH OF RIVASTIGMINE TRANSDERMAL SYSTEM, 4.6 MG/24 HRS, 9.5 MG/24 HRS AND 13.3 MG/24 HRS, A GENERIC VERSION OF NOVARTIS' EXELON PATCH.  Full Article

Lupin And Mylan Partner To Commercialize Enbrel(Etanercept) Biosimilar
Thursday, 28 Jun 2018 

June 28 (Reuters) - Mylan NV ::LUPIN AND MYLAN PARTNER TO COMMERCIALIZE ENBREL® (ETANERCEPT) BIOSIMILAR.MYLAN- WILL COMMERCIALIZE LUPIN'S PROPOSED ETANERCEPT BIOSIMILAR IN EUROPE, AUSTRALIA, NEW ZEALAND, LATIN AMERICA, AFRICA AND MOST MARKETS THROUGHOUT ASIA.MYLAN - LUPIN WILL RECEIVE AN UP-FRONT PAYMENT OF $15 MILLION AND POTENTIAL COMMERCIAL MILESTONES TOGETHER WITH AN EQUAL SHARE IN NET PROFITS OF PRODUCT..  Full Article

Mylan Says FDA Approves First Biosimilar To Neulasta
Monday, 4 Jun 2018 

June 4 (Reuters) - Mylan NV ::FDA APPROVES FIRST BIOSIMILAR TO NEULASTA TO HELP REDUCE THE RISK OF INFECTION DURING CANCER TREATMENT.U.S. FDA - GRANTED APPROVAL OF FULPHILA TO MYLAN GMBH.  Full Article

Mylan Adds To Growing Women's Healthcare Portfolio With Launch Of Generic For Oral Contraceptive Yaz
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Mylan NV ::MYLAN ADDS TO GROWING WOMEN'S HEALTHCARE PORTFOLIO WITH LAUNCH OF GENERIC FOR ORAL CONTRACEPTIVE YAZ®.MYLAN NV - U.S. LAUNCH OF DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP, 3 MG/0.02 MG, A GENERIC VERSION OF BAYER'S YAZ TABLETS.  Full Article

UPDATE 2-U.S. FDA approves Teva's generic of Mylan's EpiPen

Aug 16 The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's life-saving allergy injection, EpiPen, at a time when regulators are looking to lower healthcare costs.